Drug Profile
MEDI 1341
Alternative Names: MEDI-1341; TAK 341Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca; Takeda
- Class Antibodies; Antiparkinsonians
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple system atrophy
- No development reported Parkinson's disease
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (IV, Infusion)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (IV, Infusion)
- 22 Apr 2023 Pooled pharmacokinetics, pharmacodynamics and adverse events data from a phase I trials in Parkinson's disease and healthy volunteers presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)